Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Krognes Steve E. | CFO and Treasurer | Feb 16 | Sale | 65.09 | 50,000 | 3,254,710 | 900,000 | Feb 18 06:12 PM | BRATTON DOUGLAS K | 10% Owner | Feb 12 | Sale | 65.00 | 2,216,798 | 144,091,870 | 9,984,836 | Feb 17 08:39 PM | Ho Carole | Chief Medical Officer | Feb 11 | Sale | 70.33 | 3,156 | 221,972 | 172,233 | Feb 16 07:43 PM | Schuth Alexander O. | COO and Secretary | Feb 11 | Sale | 70.35 | 3,047 | 214,341 | 541,582 | Feb 16 07:43 PM | Krognes Steve E. | CFO and Treasurer | Feb 11 | Sale | 70.34 | 3,035 | 213,480 | 97,587 | Feb 16 07:42 PM | Watts Ryan J. | President and CEO | Feb 11 | Sale | 70.30 | 9,473 | 665,984 | 2,324,076 | Feb 16 07:40 PM | Ho Carole | Chief Medical Officer | Feb 09 | Sale | 74.68 | 1,470 | 109,785 | 167,921 | Feb 11 07:10 PM | Krognes Steve E. | CFO and Treasurer | Feb 09 | Sale | 74.68 | 1,448 | 108,135 | 12,979 | Feb 11 07:11 PM | Schuth Alexander O. | COO and Secretary | Feb 09 | Sale | 74.80 | 1,468 | 109,809 | 537,344 | Feb 11 07:13 PM | Watts Ryan J. | President and CEO | Feb 09 | Sale | 73.79 | 5,112 | 377,211 | 2,313,853 | Feb 10 07:40 PM | Watts Ryan J. | President and CEO | Feb 08 | Option Exercise | 0.00 | 14,316 | 0 | 2,318,965 | Feb 10 07:40 PM | Schuth Alexander O. | COO and Secretary | Feb 07 | Option Exercise | 0.00 | 4,250 | 0 | 538,812 | Feb 11 07:13 PM | Krognes Steve E. | CFO and Treasurer | Feb 07 | Option Exercise | 0.00 | 4,250 | 0 | 14,427 | Feb 11 07:11 PM | Ho Carole | Chief Medical Officer | Feb 07 | Option Exercise | 0.00 | 4,250 | 0 | 169,391 | Feb 11 07:10 PM | Schuth Alexander O. | COO and Secretary | Feb 04 | Sale | 67.84 | 10,000 | 678,361 | 534,562 | Feb 05 04:44 PM | Watts Ryan J. | President and CEO | Feb 01 | Sale | 68.44 | 18,334 | 1,254,819 | 2,304,649 | Feb 02 09:21 PM | Krognes Steve E. | CFO and Treasurer | Jan 15 | Sale | 71.45 | 50,000 | 3,572,556 | 950,000 | Jan 20 06:46 PM | Schuth Alexander O. | COO and Secretary | Jan 04 | Sale | 74.95 | 70,000 | 5,246,408 | 544,562 | Jan 06 06:50 PM | Watts Ryan J. | President and CEO | Jan 04 | Sale | 74.96 | 88,334 | 6,621,782 | 2,322,978 | Jan 06 06:49 PM | Schenkein David P | Director | Dec 21 | Sale | 90.01 | 5,000 | 450,027 | 26,232 | Dec 23 09:52 PM | Schenkein David P | Director | Dec 21 | Sale | 90.06 | 25,000 | 2,251,555 | 0 | Dec 23 09:52 PM | BRATTON DOUGLAS K | 10% Owner | Dec 14 | Sale | 80.38 | 17,825 | 1,432,842 | 383,411 | Dec 15 04:47 PM | BRATTON DOUGLAS K | 10% Owner | Dec 11 | Sale | 80.05 | 46,799 | 3,746,442 | 401,236 | Dec 15 04:47 PM | Schenkein David P | Director | Nov 12 | Sale | 70.05 | 30,000 | 2,101,590 | 25,000 | Nov 13 05:13 PM | Schenkein David P | Director | Nov 10 | Sale | 60.03 | 10,000 | 600,310 | 55,000 | Nov 12 04:21 PM | Schenkein David P | Director | Nov 04 | Sale | 50.18 | 10,000 | 501,830 | 65,000 | Nov 06 05:53 PM | Ho Carole | Chief Medical Officer | Oct 09 | Option Exercise | 5.28 | 30,000 | 158,400 | 196,617 | Oct 13 06:45 PM | Ho Carole | Chief Medical Officer | Oct 09 | Sale | 41.22 | 30,000 | 1,236,614 | 166,617 | Oct 13 06:45 PM | Ho Carole | Chief Medical Officer | Oct 08 | Option Exercise | 5.28 | 22,906 | 120,944 | 189,523 | Oct 13 06:45 PM | Ho Carole | Chief Medical Officer | Oct 08 | Sale | 40.12 | 22,906 | 918,989 | 166,617 | Oct 13 06:45 PM | Ho Carole | Chief Medical Officer | Sep 10 | Sale | 31.00 | 3,689 | 114,359 | 165,141 | Sep 14 09:38 PM | BRATTON DOUGLAS K | 10% Owner | Aug 12 | Sale | 31.65 | 1,443,247 | 45,678,768 | 12,201,634 | Aug 14 04:50 PM | BRATTON DOUGLAS K | 10% Owner | Jun 30 | Sale | 24.01 | 45,345 | 1,088,601 | 448,035 | Jun 30 07:17 PM | BRATTON DOUGLAS K | 10% Owner | Jun 29 | Sale | 24.01 | 82,578 | 1,982,373 | 493,380 | Jun 30 07:17 PM | BRATTON DOUGLAS K | 10% Owner | Jun 26 | Sale | 23.94 | 122,077 | 2,922,078 | 575,958 | Jun 30 07:17 PM | BRATTON DOUGLAS K | 10% Owner | Jun 23 | Sale | 25.77 | 20,024 | 515,969 | 698,035 | Jun 23 05:41 PM | BRATTON DOUGLAS K | 10% Owner | Jun 22 | Sale | 24.78 | 90,056 | 2,231,902 | 718,059 | Jun 23 05:41 PM | BRATTON DOUGLAS K | 10% Owner | Jun 19 | Sale | 24.54 | 144,920 | 3,556,503 | 808,115 | Jun 23 05:41 PM | Tessier-Lavigne Marc | Director | Jun 16 | Sale | 26.10 | 400,000 | 10,440,000 | 2,739,043 | Jun 18 09:41 PM | BRATTON DOUGLAS K | 10% Owner | Jun 05 | Sale | 25.75 | 1,922,855 | 49,513,516 | 13,644,881 | Jun 09 04:10 PM | Krognes Steve E. | CFO and Treasurer | Mar 30 | Sale | 19.48 | 1,428 | 27,817 | 1,006,488 | Apr 01 06:19 PM | Schuth Alexander O. | COO and Secretary | Mar 30 | Sale | 19.49 | 1,427 | 27,812 | 28,662 | Apr 01 06:19 PM | Watts Ryan J. | President and CEO | Mar 30 | Sale | 19.48 | 4,807 | 93,640 | 22,013 | Apr 01 06:17 PM | Ho Carole | Chief Medical Officer | Mar 30 | Sale | 19.48 | 1,428 | 27,817 | 2,822 | Apr 01 06:18 PM |
|